Joseph K Salama

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint ACR Appropriateness Criteria® thyroid carcinoma
    Joseph K Salama
    Duke University, Durham, NC, United States Electronic address
    Oral Oncol 50:577-86. 2014
  2. pmc A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer
    Pretesh R Patel
    Department of Radiation Oncology, Duke University, P O Box 3085, Durham NC 27713, USA
    Pulm Med 2012:480961. 2012
  3. pmc A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904
    Joseph K Salama
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, North Carolina 27710, USA
    J Thorac Oncol 8:1043-9. 2013
  4. pmc The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study
    Abhishek A Solanki
    Department of Radiation and Cellular Oncology, University of Chicago Medical Center, 5758 South Maryland Ave, MC 9006, Chicago IL 60637, US
    Radiat Oncol 7:216. 2012
  5. doi request reprint Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
    Joseph K Salama
    Department of Radiation Oncology, Duke University, Durham, North Carolina 27710, USA
    Cancer 118:2962-70. 2012
  6. doi request reprint A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
    J K Salama
    Department of Radiation Oncology, Duke University, Durham 27710, USA
    Ann Oncol 22:2304-9. 2011
  7. pmc Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
    Joseph K Salama
    Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 81:e269-74. 2011
  8. ncbi request reprint ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck
    Joseph K Salama
    Duke University, Durham, NC, United States
    Oral Oncol 47:554-9. 2011
  9. ncbi request reprint Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy
    Kent W Mouw
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Oral Oncol 48:1025-30. 2012
  10. ncbi request reprint Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    Int J Radiat Oncol Biol Phys 64:382-91. 2006

Detail Information

Publications41

  1. ncbi request reprint ACR Appropriateness Criteria® thyroid carcinoma
    Joseph K Salama
    Duke University, Durham, NC, United States Electronic address
    Oral Oncol 50:577-86. 2014
    ....
  2. pmc A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer
    Pretesh R Patel
    Department of Radiation Oncology, Duke University, P O Box 3085, Durham NC 27713, USA
    Pulm Med 2012:480961. 2012
    ..We call for large, intergroup, and even international randomized trials incorporating HIGRT and other metastasis-directed therapies into the treatment of patients with oligometastatic/oligo-recurrent NSCLC...
  3. pmc A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904
    Joseph K Salama
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, North Carolina 27710, USA
    J Thorac Oncol 8:1043-9. 2013
    ..We pooled data of patients assigned to receive daily RT of 70 Gy from three, consecutive prospective Cancer and Leukemia Group B L-SCLC cancer trials and report the results here...
  4. pmc The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study
    Abhishek A Solanki
    Department of Radiation and Cellular Oncology, University of Chicago Medical Center, 5758 South Maryland Ave, MC 9006, Chicago IL 60637, US
    Radiat Oncol 7:216. 2012
    ..However, the characterization of PET response following SBRT is unknown in this population. We analyzed our cohort of patients to describe the PET response following SBRT...
  5. doi request reprint Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
    Joseph K Salama
    Department of Radiation Oncology, Duke University, Durham, North Carolina 27710, USA
    Cancer 118:2962-70. 2012
    ..A subset of patients with metastatic cancer in limited organs may benefit from metastasis-directed therapy. The authors investigated whether patients with limited metastases could be safely treated with metastasis-directed radiotherapy...
  6. doi request reprint A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
    J K Salama
    Department of Radiation Oncology, Duke University, Durham 27710, USA
    Ann Oncol 22:2304-9. 2011
    ..We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX) for intermediate-stage and select T4 head and neck squamous cell cancers (HNSCC)...
  7. pmc Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
    Joseph K Salama
    Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 81:e269-74. 2011
    ..We conducted a secondary analysis of all patients to determine predictors of treatment-related pulmonary toxicity...
  8. ncbi request reprint ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck
    Joseph K Salama
    Duke University, Durham, NC, United States
    Oral Oncol 47:554-9. 2011
    ..Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients...
  9. ncbi request reprint Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy
    Kent W Mouw
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Oral Oncol 48:1025-30. 2012
    ....
  10. ncbi request reprint Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    Int J Radiat Oncol Biol Phys 64:382-91. 2006
    ....
  11. doi request reprint Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue
    Aaron W Pederson
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Head Neck 32:1519-27. 2010
    ..Our aim was to report the outcomes of base of tongue cancers treated with chemoradiotherapy...
  12. ncbi request reprint A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy
    Kiran Devisetty
    Department of Radiation and Cellular Oncology, University of Chicago, IL, USA
    Radiother Oncol 93:298-301. 2009
    ..For V(30)>450 cc and < or =450 cc, acute GI toxicity was 33% and 8%, respectively (p=0.003)...
  13. ncbi request reprint Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy
    Loren K Mell
    Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 70:1431-7. 2008
    ....
  14. ncbi request reprint Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation
    Kevin S Choe
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA
    Cancer 117:4671-8. 2011
    ..To examine potential prognostic factors associated with survival, the authors of this report retrospectively reviewed the outcomes of patients who received CReRT...
  15. ncbi request reprint Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer
    Michael D Hasselle
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA
    J Thorac Oncol 7:376-81. 2012
    ..Outcomes data treating patients with oligometastatic (≤ 5 metastases) non-small cell lung carcinoma (NSCLC) with hypofractionated image-guided radiotherapy (HIGRT) are limited...
  16. ncbi request reprint Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
    ..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck...
  17. ncbi request reprint An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease
    Joseph K Salama
    Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 14:5255-9. 2008
    ..We investigated whether cancer patients with limited sites of metastatic disease (oligometastasis) who failed standard therapies could be identified and safely treated at one to five known sites of low-volume disease with radiotherapy...
  18. doi request reprint Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer
    Aaron W Pederson
    Department of Radiation and Cellular Oncology, University of Chicago, IL, USA
    Am J Clin Oncol 34:356-61. 2011
    ..To report outcomes of oral cavity cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy (chemoIMRT)...
  19. pmc Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies
    Aaron W Pederson
    Department of Radiation Oncology, Memorial University Medical Center, 4700 Waters Avenue, Savannah, GA 31404, USA
    Head Neck Oncol 3:31. 2011
    ..To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy...
  20. doi request reprint Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer
    Kevin S Choe
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA
    Radiother Oncol 97:318-21. 2010
    ..In the postoperative setting, the efficacy of such an approach with adjuvant chemotherapy (AdjCT) followed by postoperative CCRT is unclear...
  21. ncbi request reprint Chemoreirradiation for recurrent salivary gland malignancies
    Aaron W Pederson
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Radiother Oncol 95:308-11. 2010
    ..To report our experience in treating recurrent salivary gland malignancies using concurrent chemotherapy and reirradiation...
  22. ncbi request reprint Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 25:4581-6. 2007
    ..To report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT)...
  23. ncbi request reprint Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer
    Joseph K Salama
    Department of Radiation and Cellular Oncology, 5758 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Arch Otolaryngol Head Neck Surg 134:1060-5. 2008
    ..To define factors that acutely influenced swallowing function prior to and during concurrent chemotherapy and radiotherapy...
  24. ncbi request reprint Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers
    Arif Y Shaikh
    Department of Radiation and Cellular Oncology, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Am J Clin Oncol 30:258-63. 2007
    ..For locally advanced but technically operable nonsmall cell lung cancer (NSCLC), neoadjuvant chemoradiotherapy is frequently used. Ideal radiotherapy dose in this context is unclear...
  25. ncbi request reprint Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 35:251-61. 2008
    ..Controversies, such as the utility of chemotherapy and RRT following surgical salvage, will be addressed. Finally, we will review investigations seeking to improve the therapeutic outcomes of patients treated with chemotherapy and RRT...
  26. doi request reprint New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer
    Joseph K Salama
    Duke University, Durham, NC, USA
    J Clin Oncol 31:1029-38. 2013
    ..As modern radiotherapy techniques have been shown to improve outcomes of some patients with limited metastatic disease, investigations are ongoing regarding how to optimally integrate them with standard chemotherapy platforms...
  27. doi request reprint Reirradiation for recurrent head and neck cancer
    Pretesh R Patel
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27713, USA
    Expert Rev Anticancer Ther 12:1177-89. 2012
    ..Intensity-modulated radiotherapy has been shown to reduce toxicity and improve disease control. Novel systemic therapies and radiotherapy techniques, including stereotactic body radiotherapy, are under active study...
  28. doi request reprint Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer
    Kent W Mouw
    Department of Radiation Oncology, Duke University Medical Center, PO Box 3085, Durham, NC 27710, USA
    Arch Otolaryngol Head Neck Surg 136:1226-34. 2010
    ..to identify factors that influence patient-centered measures of speech and swallowing function after successful use of chemoradiotherapy to treat cancers of the head and neck...
  29. ncbi request reprint Stereotactic body radiotherapy: a critical review for nonradiation oncologists
    John P Kirkpatrick
    Department of Radiation Oncology, Duke Cancer Institute, and the Durham VA Medical Center, Durham, North Carolina
    Cancer 120:942-54. 2014
    ....
  30. doi request reprint Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium
    Michael A Samuels
    Department of Radiation Oncology, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Clin Lung Cancer 14:446-51. 2013
    ..This study was a retrospective analysis of elderly patients treated with stereotactic body radiotherapy (SBRT) in the setting of a multi-institutional consortium...
  31. ncbi request reprint A rationale for the targeted treatment of oligometastases with radiotherapy
    Dhara M Macdermed
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
    J Surg Oncol 98:202-6. 2008
    ....
  32. doi request reprint Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions
    Junsheng Cao
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Med Dosim 34:126-32. 2009
    ..With this model, the dosimetric coverage difference introduced by respiratory motion could be evaluated during patient CT simulation. An appropriate treatment method can be chosen after the simulation...
  33. ncbi request reprint Chemoradiotherapy for locally advanced head and neck cancer
    Joseph K Salama
    Department of Radiation and Cellular Oncology, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637 1470, USA
    J Clin Oncol 25:4118-26. 2007
  34. ncbi request reprint Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637 1407, USA
    Int J Radiat Oncol Biol Phys 65:1170-6. 2006
    ..The aim of this article is to report a preliminary analysis of our initial clinical experience with extended-field intensity-modulated radiotherapy for gynecologic malignancies...
  35. doi request reprint Advances in radiotherapy for tumors involving the mediastinum
    Kevin S Choe
    Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue, MC 9006, Chicago, IL 60637, USA
    Thorac Surg Clin 19:133-41. 2009
    ..New technologies and radiation modalities may help achieve disease control more safely and effectively...
  36. doi request reprint Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies
    Chris R Kelsey
    Department of Radiation Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
    Surg Oncol Clin N Am 22:463-81. 2013
    ..Ongoing studies are examining whether SBRT can replace surgery for certain patients, the optimal dose-fractionation scheme, and how best to treat patients having central tumors near the primary tracheobronchial tree...
  37. doi request reprint Stereotactic body radiotherapy treatment of extracranial metastases
    Joseph K Salama
    Department of Radiation Oncology, Box 3085, Duke Cancer Institute, Durham, NC 27710, USA
    Nat Rev Clin Oncol 9:654-65. 2012
    ..Further investigations are also needed to understand the basic biological mechanisms underlying SBRT because they are likely to be different to those mechanisms in conventional radiotherapy...
  38. ncbi request reprint Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 103:664-71. 2005
    ..Therefore, the authors analyzed the impact of the number of tumor-free axillary lymph nodes on disease-free survival (DFS) in two distinct patient populations...
  39. pmc Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy
    Stephen J Freedland
    Department of Surgery, Durham VA Medical Center, Durham, North Carolina, USA
    Int J Radiat Oncol Biol Phys 86:848-53. 2013
    ....
  40. doi request reprint Predictors of competing mortality in advanced head and neck cancer
    Loren K Mell
    University of California San Diego, Moores Cancer Center, Department of Radiation Oncology, 3855 Health Sciences Dr MC 0843, La Jolla, CA 92129, USA
    J Clin Oncol 28:15-20. 2010
    ..Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials...
  41. ncbi request reprint Intensity-modulated radiation therapy in gynecologic malignancies
    Joseph K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue, MC 9006, Chicago, IL 60637, USA
    Curr Treat Options Oncol 5:97-108. 2004
    ..Although further work is needed, these results suggest that IMRT may represent a major advancement in the planning and delivery of radiation therapy in patients with gynecologic malignancies...